CN116970559A - Induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof - Google Patents
Induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof Download PDFInfo
- Publication number
- CN116970559A CN116970559A CN202311222948.7A CN202311222948A CN116970559A CN 116970559 A CN116970559 A CN 116970559A CN 202311222948 A CN202311222948 A CN 202311222948A CN 116970559 A CN116970559 A CN 116970559A
- Authority
- CN
- China
- Prior art keywords
- adipose
- mesenchymal stem
- medium
- derived mesenchymal
- induction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 60
- 230000006698 induction Effects 0.000 title claims abstract description 43
- 239000001963 growth medium Substances 0.000 claims abstract description 33
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 23
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 claims abstract description 21
- 229960000812 linaclotide Drugs 0.000 claims abstract description 21
- 108010024409 linaclotide Proteins 0.000 claims abstract description 21
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims abstract description 20
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims abstract description 20
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 13
- 229930091371 Fructose Natural products 0.000 claims abstract description 13
- 239000005715 Fructose Substances 0.000 claims abstract description 13
- 102000004338 Transferrin Human genes 0.000 claims abstract description 13
- 108090000901 Transferrin Proteins 0.000 claims abstract description 13
- 239000012581 transferrin Substances 0.000 claims abstract description 13
- 108010024636 Glutathione Proteins 0.000 claims abstract description 10
- 229960003180 glutathione Drugs 0.000 claims abstract description 10
- 239000002609 medium Substances 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 25
- 210000000577 adipose tissue Anatomy 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 239000007640 basal medium Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 abstract description 11
- 102000004127 Cytokines Human genes 0.000 abstract description 11
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 20
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 9
- 101800003838 Epidermal growth factor Proteins 0.000 description 9
- 229940116977 epidermal growth factor Drugs 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 7
- 229940126864 fibroblast growth factor Drugs 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an induction culture medium for preparing adipose-derived mesenchymal stem cell factor, which comprises a basal culture medium and the following components added in the culture medium: linaclotide, sesamol, fructose, transferrin, glutathione. The linaclotide and sesamol are added into the culture medium to obviously stimulate the adipose-derived mesenchymal stem cells to secrete cytokines, so that the capacity of secreting cytokines by the adipose-derived mesenchymal stem cells is improved, the content of the cytokines in the culture medium is improved, and convenience is provided for the concentration application of the cytokines.
Description
Technical Field
The invention relates to the field of stem cells, in particular to an induction medium for preparing adipose-derived mesenchymal stem cell factors and application thereof.
Background
Mesenchymal stem cells are multipotent stem cells that share all the common properties of stem cells, namely self-renewal and multipotent differentiation. The application of the recombinant strain is the most in clinical application, and the recombinant strain can be combined with hematopoietic stem cells, so that the success rate of transplantation can be improved, and hematopoietic reconstitution can be accelerated. When the patient receives the large-dose chemotherapy, the mesenchymal stem cells and the hematopoietic stem cells are infused together, so that the recovery time of the blood cells of the patient can be obviously accelerated, and the method is safe and has no adverse reaction. Mesenchymal stem cells exist in various tissues (such as bone marrow, umbilical cord blood and umbilical cord tissue, placenta tissue, adipose tissue, etc.), and have a multidirectional differentiation potential, and are adult stem cells of non-hematopoietic stem cells. The stem cells have the potential of differentiating into various mesenchymal series cells (such as osteoblasts, chondroblasts, adipoblasts and the like) or non-mesenchymal series cells, and have unique cytokine secretion functions.
Adipose-derived stem cells refer to mesenchymal stem cells existing in adipose tissues, and studies have shown that adipose-derived stem cells can secrete various cytokines such as EGF epidermal growth factor, TGF-beta 1 transforming growth factor beta 1, FGF fibroblast growth factor, VEGF vascular endothelial growth factor, PDGF platelet-derived growth factor, etc. The adipose-derived mesenchymal stem cells secrete active factors and have the functions of improving inflammatory environment, regulating organism immune state, inhibiting apoptosis, promoting cell proliferation, promoting blood vessel regeneration, promoting wound healing and the like.
However, there are problems in the present adipose-derived mesenchymal stem cells, such as low content, unstable property and poor activity of the cytokines although the adipose-derived mesenchymal stem cells contain more cytokines, which greatly limit the wide clinical application of the cytokines of the adipose-derived mesenchymal stem cells.
Disclosure of Invention
In order to solve the problems, the invention provides an induction medium for preparing adipose-derived mesenchymal stem cell factors and application thereof, which can promote the adipose-derived mesenchymal stem cells to secrete the cell factors and can improve the content of the cell factors in cell fluid.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
an induction medium for preparing adipose-derived mesenchymal stem cell factor, comprising a basal medium and the following components added in the medium: linaclotide, sesamol, fructose, transferrin, glutathione.
Further, the basic culture medium is a DMEM/F12 culture medium, and the contents of each component in the culture medium are as follows: linaclotide 0.5-3.5 μg/mL, sesamol 1.2-4.8 μg/mL, transferrin 2.4-6.5 μg/mL, fructose 5.5-10ng/mL, glutathione 10-20ng/mL.
Preferably, the contents of each component in the culture medium are as follows: linaclotide 2.5 μg/mL, sesamol 3.7 μg/mL, transferrin 5.5 μg/mL, fructose 7ng/mL, glutathione 15ng/mL.
The application of the induction culture medium for preparing the adipose-derived mesenchymal stem cell factor comprises the following steps:
(1) Isolating adipose mesenchymal stem cells;
(2) Subculturing the adipose-derived mesenchymal stem cells until the cell confluence is 70-80%, and discarding the culture medium;
(3) And (3) inoculating the adipose-derived mesenchymal stem cells in the step (2) into the induction culture medium for induction culture.
Preferably, step (2) is subculturing to the adipose mesenchymal stem cells of the P2-P5 generation.
Preferably, the induction culture of step (3) is at 37℃with 5% CO 2 Is carried out under the condition of (2).
Preferably, the cell density in the induction medium in step (3) is 1-5X 10 5 And each mL.
Preferably, the induction culture time in step (3) is 3-5d.
Compared with the prior art, the invention has the beneficial effects that: the invention provides an induction culture medium for preparing adipose-derived mesenchymal stem cell factors and application thereof, and linaclotide and sesamol are added in the culture medium to obviously stimulate the adipose-derived mesenchymal stem cells to secrete the cell factors, so that the capacity of secreting the cell factors by the adipose-derived mesenchymal stem cells is improved, the content of the cell factors in a culture solution is improved, and convenience is provided for the concentration application of the cell factors.
Drawings
FIG. 1 is the EGF (epidermal growth factor) content in the cell culture solutions of comparative examples 1 to 6 according to example 1 of the present invention;
FIG. 2 shows the TGF-. Beta.1 (transforming growth factor-. Beta.1) content of the cell culture broth of comparative examples 1 to 6 according to example 1 of the present invention;
FIG. 3 shows the FGF (fibroblast growth factor) content of the cell culture solutions of comparative examples 1 to 6 according to example 1 of the present invention.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and detailed description, wherein it is to be understood that, on the premise of no conflict, the following embodiments or technical features may be arbitrarily combined to form new embodiments.
Example 1, an induction medium for the preparation of adipose-derived mesenchymal stem cell factor, comprising a basal medium and the following components added to the medium: linaclotide, sesamol, fructose, transferrin, glutathione; the basic culture medium is a DMEM/F12 culture medium, and the contents of each component in the culture medium are as follows: linaclotide 2.5 μg/mL, sesamol 3.7 μg/mL, transferrin 5.5 μg/mL, fructose 7ng/mL, glutathione 15ng/mL;
the application of the induction culture medium for preparing the adipose-derived mesenchymal stem cell factor comprises the following steps:
(1) Isolation of adipose-derived mesenchymal stem cells: adding normal saline into adipose tissue for cleaning, packaging adipose tissue into centrifuge tube, adding 0.5% type I collagenase, digesting at normal temperature for 30min, centrifuging, collecting bottom layer precipitated adipose mesenchymal stem cells, adding complete medium (DMEM/F12 medium+10% FBS), and resuspending to obtain a cell density of 1×10 4 Individual/mL, at 37 ℃,5% CO 2 Culturing under the condition;
(2) After the confluence of the adipose-derived mesenchymal stem cells in the step (1) reaches 80%, carrying out subculture, wherein the subculture ratio is 1:3, and discarding the culture medium after the confluence of the cells of the P3 generation is 70%;
(3) Resuspending the adipose-derived mesenchymal stem cells of step (2) with the above-mentioned induction medium to a cell density of 1×10 5 Inoculating 1mL of culture medium in 24-well plate at 37deg.C and 5% CO 2 Is induced to culture for 4d.
Example 2, an induction medium for the preparation of adipose-derived mesenchymal stem cell factor, comprising a basal medium and the following components added to the medium: linaclotide, sesamol, fructose, transferrin, glutathione; the basic culture medium is a DMEM/F12 culture medium, and the contents of each component in the culture medium are as follows: linaclotide 0.5 μg/mL, sesamol 1.2 μg/mL, transferrin 2.4 μg/mL, fructose 5.5ng/mL, glutathione 10ng/mL;
the application of the induction culture medium for preparing the adipose-derived mesenchymal stem cell factor comprises the following steps:
(1) Isolation of adipose-derived mesenchymal stem cells: adding normal saline into adipose tissue for cleaning, packaging adipose tissue into centrifuge tube, adding 0.5% type I collagenase, digesting at normal temperature for 30min, centrifuging, collecting bottom layer precipitated adipose mesenchymal stem cells, adding complete medium (DMEM/F12 medium+10% FBS), and resuspending to obtain a cell density of 1×10 4 Individual/mL, at 37 ℃,5% CO 2 Culturing under the condition;
(2) After the confluence of the adipose-derived mesenchymal stem cells in the step (1) reaches 80%, carrying out subculture, wherein the subculture ratio is 1:3, and discarding the culture medium after the confluence of the cells of the P2 generation is 75%;
(3) Resuspending the adipose-derived mesenchymal stem cells of step (2) with the above-mentioned induction medium to a cell density of 3×10 5 Inoculating 1mL of culture medium in 24-well plate at 37deg.C and 5% CO 2 Is induced to culture for 3d.
Example 3, an induction medium for the preparation of adipose-derived mesenchymal stem cell factor, comprising a basal medium and the following components added to the medium: linaclotide, sesamol, fructose, transferrin, glutathione; the basic culture medium is a DMEM/F12 culture medium, and the contents of each component in the culture medium are as follows: linaclotide 3.5 μg/mL, sesamol 4.8 μg/mL, transferrin 6.5 μg/mL, fructose 10ng/mL, glutathione 20ng/mL;
the application of the induction culture medium for preparing the adipose-derived mesenchymal stem cell factor comprises the following steps:
(1) Isolation of adipose-derived mesenchymal stem cells: adding normal saline into adipose tissue for cleaning, packaging adipose tissue into centrifuge tube, adding 0.5% type I collagenase, digesting at normal temperature for 30min, centrifuging, collecting bottom layer precipitated adipose mesenchymal stem cells, adding complete medium (DMEM/F12 medium+10% FBS), and resuspending to obtain a cell density of 1×10 4 Individual/mL, at 37 ℃,5% CO 2 Culturing under the condition;
(2) After the confluence of the adipose-derived mesenchymal stem cells in the step (1) reaches 80%, carrying out subculture, wherein the subculture ratio is 1:3, and discarding the culture medium after the confluence of the cells of the P5 generation is 80%;
(3) Resuspending the adipose-derived mesenchymal stem cells of step (2) with the above-mentioned induction medium to a cell density of 5×10 5 Inoculating 1mL of culture medium in 24-well plate at 37deg.C and 5% CO 2 Is induced to culture for 5d.
Comparative example 1 is an induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof, and the difference from example 1 is that: linaclotide 0 μg/mL, otherwise the same as in example 1.
Comparative example 2 is an induction medium for preparing adipose-derived mesenchymal stem cell factor and its application, and the difference from example 1 is: linaclotide 5 μg/mL, the same as in example 1.
Comparative example 3 is an induction medium for preparing adipose-derived mesenchymal stem cell factor and its application, and the difference from example 1 is: sesamol 0. Mu.g/mL, and the same as in example 1.
Comparative example 4 is an induction medium for preparing adipose-derived mesenchymal stem cell factor and its application, and the difference from example 1 is that: the amount of sesamol was adjusted to 6.2. Mu.g/mL without addition of linaclotide.
Comparative example 5 is an induction medium for preparing adipose-derived mesenchymal stem cell factor and its application, and the difference from example 1 is that: the amount of linaclotide was adjusted to 6.2. Mu.g/mL without adding sesamol.
Comparative example 6 is an induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof, and the difference from example 1 is that: linaclotide and sesamol were not added.
The adipose-derived mesenchymal stem cells of example 1, comparative examples 1 to 6 were subjected to cell counting by trypan blue staining after completion of induction culture, respectively, and the cell viability was counted, and the results are shown in table 1.
TABLE 1
| Group of | Cell number (. Times.10) 5 Personal computer | Cell viability (%) |
| Example 1 | 1.63 | 98.29% |
| Comparative example 1 | 1.59 | 98.06% |
| Comparative example 2 | 1.61 | 97.83% |
| Comparative example 3 | 1.46 | 97.29% |
| Comparative example 4 | 1.57 | 98.15% |
| Comparative example 5 | 1.42 | 97.72% |
| Comparative example 6 | 1.39 | 97.24% |
It can be seen from Table 1 that the cell viability is not greatly different in example 1 and comparative examples 1 to 6, and that example 1 is superior to comparative examples 1 to 6 in terms of cell number.
The cell culture solutions of example 1 and comparative examples 1 to 6 were collected after centrifugation, and the contents of EGF (epidermal growth factor), TGF-. Beta.1 (transforming growth factor-. Beta.1) and FGF (fibroblast growth factor) were measured using ELISA kit, and the results are shown in FIGS. 1 to 3.
As can be seen from fig. 1 to 3, the contents of EGF (epidermal growth factor), TGF- β1 (transforming growth factor β1) and FGF (fibroblast growth factor) in example 1 are higher than those in comparative examples 1 to 6, which shows that the induction medium of the present invention effectively improves the capacity of the adipose-derived mesenchymal stem cells to secrete cytokines by adding linaclotide and sesamol, and the increase of the cytokines content in the culture solution is higher, especially the increase of the EGF (epidermal growth factor) content is most obvious.
The above embodiments are only preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, but any insubstantial changes and substitutions made by those skilled in the art on the basis of the present invention are intended to be within the scope of the present invention as claimed.
Claims (8)
1. An induction medium for preparing adipose-derived mesenchymal stem cell factor, which is characterized by comprising a basal medium and the following components added in the medium: linaclotide, sesamol, fructose, transferrin, glutathione.
2. The induction medium for preparing adipose-derived mesenchymal stem cell factor according to claim 1, wherein the basal medium is DMEM/F12 medium, and the contents of each component in the medium are as follows: linaclotide 0.5-3.5 μg/mL, sesamol 1.2-4.8 μg/mL, transferrin 2.4-6.5 μg/mL, fructose 5.5-10ng/mL, glutathione 10-20ng/mL.
3. The induction medium for preparing adipose-derived mesenchymal stem cell factor according to claim 2, wherein the contents of each component in the medium are: linaclotide 2.5 μg/mL, sesamol 3.7 μg/mL, transferrin 5.5 μg/mL, fructose 7ng/mL, glutathione 15ng/mL.
4. Use of an induction medium for the preparation of adipose-derived mesenchymal stem cell factor according to claims 1 to 3, characterized by comprising the steps of:
(1) Isolating adipose mesenchymal stem cells;
(2) Subculturing the adipose-derived mesenchymal stem cells until the cell confluence is 70-80%, and discarding the culture medium;
(3) Inoculating the adipose-derived mesenchymal stem cells of step (2) into the induction medium of any one of claims 1 to 3 for induction culture.
5. The use of the induction medium for preparing adipose tissue stem cell factor according to claim 4, wherein the step (2) is subculturing to P2-P5 generation adipose tissue stem cells.
6. The use of the induction medium for preparing adipose-derived mesenchymal stem cell factor according to claim 4, wherein the induction culture of step (3) is performed at 37℃with 5% CO 2 Is carried out under the condition of (2).
7. The use of the induction medium for preparing adipose-derived mesenchymal stem cell factor according to claim 4, wherein the cell density in the induction medium in the step (3) is 1 to 5×10 5 And each mL.
8. The use of the induction medium for preparing adipose tissue-derived stem cell factor according to claim 4, wherein the induction culture time in the step (3) is 3-5d.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311222948.7A CN116970559B (en) | 2023-09-21 | 2023-09-21 | Induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311222948.7A CN116970559B (en) | 2023-09-21 | 2023-09-21 | Induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116970559A true CN116970559A (en) | 2023-10-31 |
| CN116970559B CN116970559B (en) | 2023-11-28 |
Family
ID=88476902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311222948.7A Active CN116970559B (en) | 2023-09-21 | 2023-09-21 | Induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116970559B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104263697A (en) * | 2014-09-18 | 2015-01-07 | 胡振波 | Induction culture medium and method for inducing human fat mesenchymal stem cells to generate insulin secreting cells |
| CN108251359A (en) * | 2017-12-20 | 2018-07-06 | 上海华新生物高技术有限公司 | A kind of mesenchymal stem cell serum-free culture medium and cultural method |
| CN109852654A (en) * | 2018-12-28 | 2019-06-07 | 广州润虹医药科技股份有限公司 | Composition and its application of stem cell secretion cell factor can be induced |
| US20190192691A1 (en) * | 2016-04-11 | 2019-06-27 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN112481206A (en) * | 2020-12-16 | 2021-03-12 | 郑州佐爵生物科技有限公司 | Culture medium and culture method for inducing secretion of adipose-derived mesenchymal stem cell factor |
| CN114438025A (en) * | 2022-02-22 | 2022-05-06 | 辛志远 | Induction medium and culture method for preparing adipose-derived mesenchymal stem cell factor |
| US20230174971A1 (en) * | 2018-02-02 | 2023-06-08 | Lonza Ltd | Methods of cell selection and modifying cell metabolism |
-
2023
- 2023-09-21 CN CN202311222948.7A patent/CN116970559B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104263697A (en) * | 2014-09-18 | 2015-01-07 | 胡振波 | Induction culture medium and method for inducing human fat mesenchymal stem cells to generate insulin secreting cells |
| US20190192691A1 (en) * | 2016-04-11 | 2019-06-27 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN108251359A (en) * | 2017-12-20 | 2018-07-06 | 上海华新生物高技术有限公司 | A kind of mesenchymal stem cell serum-free culture medium and cultural method |
| US20230174971A1 (en) * | 2018-02-02 | 2023-06-08 | Lonza Ltd | Methods of cell selection and modifying cell metabolism |
| CN109852654A (en) * | 2018-12-28 | 2019-06-07 | 广州润虹医药科技股份有限公司 | Composition and its application of stem cell secretion cell factor can be induced |
| CN112481206A (en) * | 2020-12-16 | 2021-03-12 | 郑州佐爵生物科技有限公司 | Culture medium and culture method for inducing secretion of adipose-derived mesenchymal stem cell factor |
| CN114438025A (en) * | 2022-02-22 | 2022-05-06 | 辛志远 | Induction medium and culture method for preparing adipose-derived mesenchymal stem cell factor |
Non-Patent Citations (2)
| Title |
|---|
| RACHMAWATI NOVERINA等: "Growth factors profile in conditioned medium human adipose tissue-derived mesenchymal stem cells (CM-hATMSCs)", CLINICAL NUTRITION EXPERIMENTAL, pages 34 - 44 * |
| 赵亮 等: "TGF-β1诱导藻酸钙凝胶负载的脂肪干细胞向软骨细胞分化的研究", 中国实用医药, vol. 4, no. 18, pages 143 - 145 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116970559B (en) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Danišovič et al. | Comparison of in vitro chondrogenic potential of human mesenchymal stem cells derived from bone marrow and adipose tissue | |
| Correia et al. | Human adipose‐derived cells can serve as a single‐cell source for the in vitro cultivation of vascularized bone grafts | |
| CN110179826B (en) | Human umbilical cord mesenchymal stem cell source stem cell factor microvesicle preparation and preparation method thereof | |
| CN103695369B (en) | Umbilical cord mesenchymal stem cells vitro culture and amplification method | |
| CN107418930B (en) | Preparation method for purifying and amplifying human mesenchymal stem cells | |
| CN113564111B (en) | Method for culturing umbilical cord-derived mesenchymal stem cells in low-oxygen mode | |
| CN110938590B (en) | Mesenchymal stem cell serum-free medium and application thereof | |
| CN106924285A (en) | A kind of placenta mesenchyma stem cell parenteral solution and its preparation method and application | |
| CN112262211A (en) | Method for inducing or improving wound healing property of mesenchymal stem cells | |
| CN107267453A (en) | A kind of culture medium and its application for being used to cultivate fat mesenchymal stem cell | |
| CN111826348A (en) | In-vitro efficient preparation method and application of mesenchymal stem cells derived from human induced pluripotent stem cells | |
| CN113151165B (en) | Culture medium and culture method for human umbilical cord mesenchymal stem cell amplification | |
| CN112391340A (en) | Mesenchymal stem cell culture medium | |
| CN113736729A (en) | Composition, stem cell serum-free culture medium containing composition and stem cell culture method | |
| KR20150029280A (en) | Autologous and allogenic adipose tissue-derived mesenchymal stem cells composition for treatment of diabetic wound | |
| CN116970559B (en) | Induction medium for preparing adipose-derived mesenchymal stem cell factor and application thereof | |
| CN107674858B (en) | Separation medium and separation method of bone marrow endothelial progenitor cells | |
| CN114451402A (en) | Adipose-derived mesenchymal stem cell preservation solution and preparation method and application thereof | |
| CN102021143A (en) | Pretreatment method for improving migration capability of mesenchymal stem cells | |
| CN104830762A (en) | Propagation culture method of fat primitive mesenchymal stem cell | |
| CN101649305B (en) | Method for amplifying megakaryocyte progenitor cell from human cord blood CD34<+> cell | |
| CN100453640C (en) | Method of separating multipotent adult progenitor cells from umbilical cord blood | |
| CN112481206A (en) | Culture medium and culture method for inducing secretion of adipose-derived mesenchymal stem cell factor | |
| CN113652396B (en) | Adipose-derived mesenchymal stem cell osteogenesis inducing composition and osteogenesis inducing method | |
| CN114438025B (en) | Induction medium for preparing adipose-derived mesenchymal stem cell factor and culture method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |